Table 1.
Summary of patients' details
| Patient ID | FAB | WBC, × 109 cells/L | Karyotype** | Risk group |
|---|---|---|---|---|
| Engrafters | ||||
| 1*†‡ | 1 | 151 | Normal | Intermediate |
| 2§† | 1 | 14.7 | t(6;9) | Intermediate |
| 3 | 1 | 20.3 | –5q | Poor |
| 4 | 1 | 64 | FK | Intermediate |
| 5∥ | 1 | 37 | FK | Intermediate |
| 6∥ | 1 | 5.3 | Normal | Intermediate |
| 7§ | 1 | 139 | +13 | Intermediate |
| 8* | 2 | 104 | Normal | Intermediate |
| 9§¶∥ | 2 | 66 | t(8;21) | Good |
| 10§∥ | 2 | 27 | +11+13 | Intermediate |
| 11∥ | 2 | 39.8 | Normal | Intermediate |
| 12 | 2 | 29 | t(8;9) | Intermediate |
| 13 | 2 | 40 | t(2;3) | Poor |
| 14∥ | 4 | 2.5 | Normal | Intermediate |
| 15∥ | 4 | 71 | +3+10 | Intermediate |
| 16 | 4 | 8.5 | Normal | Intermediate |
| 17¶∥ | 4 | 221 | Normal | Intermediate |
| 18†‡ | 4 | 42.9 | Normal | Intermediate |
| 19*¶∥ | 5 | 3.9 | Complex | Poor |
| 20†‡ | 5 | 115 | Normal | Intermediate |
| 21∥ | 5 | 33 | Normal | Intermediate |
| 22 | 5 | 212 | ND | Intermediate |
| 23 | 5 | 53.7 | t(9;11) | Intermediate |
| 24∥ | 5a | 42.9 | t(11;19) | Intermediate |
| 25 | 5a | 124 | +11 | Intermediate |
| 26* | tAML | 2.7 | t(11;19) | Intermediate |
| 27∥ | tAML | 25 | t(6;11) | Intermediate |
| 28*∥ | tAML | 19.5 | Complex | Poor |
| 29∥ | AML/MDS | 31 | Inv(3); –7 | Poor |
| Nonengrafters | ||||
| 30∥ | 0 | 70 | –9q +19 | Intermediate |
| 31 | 1 | 103 | +13 | Intermediate |
| 32# | 1 | 10 | –9q | Intermediate |
| 33# | 1 | 86 | +8 | Intermediate |
| 34#‡∥ | 1 | 6.1 | Normal | Intermediate |
| 35#∥ | 1 | 1.4 | Normal | Intermediate |
| 36§ | 1 | 50 | Normal | Intermediate |
| 37¶†‡ | 1 | 248 | Normal | Intermediate |
| 38∥ | 1 | 70 | t(8;21) | Good |
| 39∥ | 2 | 27.9 | t(8;21) | Good |
| 40∥ | 2 | 85 | +12+21 | Intermediate |
| 41 | 2 | 28 | t(8;21) | Good |
| 42∥ | 2 | 11.8 | Normal | Intermediate |
| 43 | 2 | 71 | Normal | Intermediate |
| 44† | 2 | 19.2 | t(6;9) | Intermediate |
| 45 | 2 | 5.7 | t(8;21) | Good |
| 46‡∥ | 2 | 5.5 | Normal | Intermediate |
| 47 | 2 | 3 | Normal | Intermediate |
| 48 | 3 | 1 | t(15;17) | Good |
| 49 | 3 | 1.3 | t(15;17) | Good |
| 50# | 3 | 1.9 | t(15;17) | Good |
| 51 | 3 | 6.1 | t(15;17) | Good |
| 52# | 3v | 35 | t(15;17) | Good |
| 53 | 4 | 61 | Inv 16 | Good |
| 54*‡ | 4 | 85 | Normal | Intermediate |
| 55 | 4 | 127 | Normal | Intermediate |
| 56 | 4 | 113 | Inv(16) | Good |
| 57 | 5a | 184 | ins(10;11) | Intermediate |
| 58# | 5a | 39 | +5; +8; +19 | Intermediate |
| 59∥ | tAML | 147 | Normal | Intermediate |
Mice were injected with 107 peripheral blood nucleated cells from the peripheral blood of AML patients. Murine marrows were analyzed 6 weeks after transplantation for the presence of human hematopoietic cells. AML engraftment was defined as the presence of human CD33+/CD45+ myeloid cells without an accompanying CD19+/CD45+ B-cell population. Prognosis risk group was defined as poor, intermediate, or good via karyotype according to Grimwade et al.10 Patients in whom the WBC was less than 2 × 109/L also had their bone marrow cells tested for engraftment capacity, with identical results to the peripheral blood data. All AML cases were assessed for NOD/SCID engraftment potential before any chemotherapy. FK indicates failed karyotype at diagnosis.
Patients given supportive care only
Patients possessed an FLT3-ITD
Patients had a mutated nucleophosmin gene
Patients in relapse
Patients were tested for FLT3 mutations and were found to be negative
Patients underwent affymetrix analysis
Patients produced normal engraftment in NOD/SCID mice
Full karyotyping according to the international system for human genotype nomenclature may be found in Table S1